Cover Image
市場調查報告書

動脈血栓症:開發中產品分析

Arterial Thrombosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 293894
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
動脈血栓症:開發中產品分析 Arterial Thrombosis - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 45 Pages
簡介

動脈血栓症是動脈上產生了血塊,造成脈搏不整、肌肉酸痛、肌肉痙攣,皮膚蒼白,發冷等症狀。血塊發生的部位不同,會引發腦中風、心臟病發作、末稍動脈疾病(PAD)等各種不同的重症。吸煙及肥胖、糖尿病、高血壓、高膽固醇等是致病要素,治療法有血栓溶解藥及手術等。

本報告涵括全球動脈血栓症治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

簡介

  • 調查範圍

動脈血栓症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中的治療藥:各企業
  • 開發中的治療藥:各大學·研究機關
  • 開發中的產品:各企業
  • 開發中的產品:各大學·研究機關

動脈血栓症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

動脈血栓症:開發治療藥的企業

  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai
  • Johnson & Johnson
  • Sanofi
  • Thromboserin Ltd

藥物簡介

  • 產品概要
  • 作用機制
  • R&D的進展

動脈血栓症:暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9117IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H1 2017, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape.

Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arterial Thrombosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arterial Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arterial Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arterial Thrombosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arterial Thrombosis - Overview
    • Arterial Thrombosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Arterial Thrombosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Arterial Thrombosis - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co Ltd
    • Johnson & Johnson
    • Sanofi
    • Thromboserin Ltd
  • Arterial Thrombosis - Drug Profiles
    • AB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-1468240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1213790 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-654457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-884775 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-5539 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ER-410660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-375 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PZ-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-216471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Arterial Thrombosis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Arterial Thrombosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Arterial Thrombosis - Pipeline by Astellas Pharma Inc, H1 2017
  • Arterial Thrombosis - Pipeline by Bayer AG, H1 2017
  • Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Arterial Thrombosis - Pipeline by Eisai Co Ltd, H1 2017
  • Arterial Thrombosis - Pipeline by Johnson & Johnson, H1 2017
  • Arterial Thrombosis - Pipeline by Sanofi, H1 2017
  • Arterial Thrombosis - Pipeline by Thromboserin Ltd, H1 2017
  • Arterial Thrombosis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Arterial Thrombosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top